 |
About Us |  |
|
Donate | |
|
Volunteer | |
|
Newsletter | |
|
JDA Magazine | |
 |
Join JDA |
Dr. Peter A Gottlieb
Dr. Peter A GottliebAssociate Professor of Pediatrics and Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO
University of Pennsylvania B.S. 1980 Biology
University of Medicine & Dentistry of New Jersey M.D. 1984 Medicine
A. Positions and Honors
Positions and Employment
1984-1987 Internship and Residency Training in Internal Medicine, University of Massachusetts Medical Center, Worcester, MA
1987-1990 Clinical Fellow in Endocrinology and Diabetes, University of Massachusetts Medical Center, Worcester, MA
1987-1990 Research Fellow in Diabetes, University of Massachusetts Medical, Worcester, MA
1987-1990 Instructor in Medicine, University of Massachusetts Medical Center, Worcester, MA
1990-1992 Postdoctoral Fellowship, Weizmann Institute of Science, Rehovot, Israel
1990-1992 Visiting Scientist, Weizmann Institute of Science, Rehovot, Israel
1992-1994 Assistant Professor of Medicine, University of Massachusetts Medical Center, Worcester, MA
1994-2002 Assistant Professor of Pediatrics and Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO
2002-present Associate Professor of Pediatrics and Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO
Other Experiences and Professional Memberships
1982-1984 American Medical Student Association Task Force on Aging, National Co-Chairperson
American Diabetes Association
Juvenile Diabetes Research Foundation International
Immunology of Diabetes Society
European Association for Study of Diabetes
American College of Physicians
American Federation for Medical Research
Massachusetts Medical Society
2000-ongoing Colorado Multiple Institutional Review Board (COMIRB)
2001-ongoing DPT-1/TrialNet National Steering Committee
2001 6th International Immunology of Diabetes Society Congress, American Diabetes Association Research Symposium, Local Organizing Committees
Honors
1980 Cum Laude, University of Pennsylvania
1981,1982 UMDNJ Summer Research Fellowship
1990-1992 Juvenile Diabetes Foundation International Postdoctoral Fellowship
1995-1996 Kovler Family Fellowship
1997- Honoree, ADA Colorado Affiliate Golden Ball
B. Selected peer-reviewed publications (in chronological order)
1. Roep BO, Atkinson, MR, Van Endert P, Gottlieb PA, Wilson B and Sachs J. 1999. Autoreactive T-cell responses in insulin-dependent diabetes mellitus Report of the First International Workshop for Standardization of T-cell assays. Journal of Autoimmunity. 13: 267-282.
2. Redondo MJ, Gottlieb PA, Motheral T, Mulgrew C, Rewers M, Babu S, Stephens E, Wegmann DR, and Eisenbarth GS. 1999. Heterophile Antibodies (“HAMA”) May Interfere with Cytokine Measurements in Patients with HLA Alleles Protective for Type 1A Diabetes. Diabetes. 48:2166-2170.
3. Abiru N, Wegmann D, Kawasaki E, Gottlieb P, Simone E, Kappler J and Eisenbarth GS. 2000. Dual Overlapping Peptides Recognized by Insulin peptide B:9-23 AV13S3 T Cell Clones of the NOD Mouse. Journal of Autoimmunity 14(3): 231-237.
4. Garg SK, Anderson JH, MacKenzie TA, Gerard LA, Gottlieb PA, Jennings MK, Chase HP. 2000. Impact of Humalog insulin on HbA1c values in insulin pump users. Diabetes, Obesity and Metabolism 2 (5) 307-312.
5. Stephens E, Robinson J, Gottlieb PA. 2001. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study. Journal of Diabetes Complications. Jan-Feb; 15 (1): 55-6.
6. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL and Gaur A. 2001. A Disease-Associated Cellular Immune Response in Type 1 Diabetics to An Immunodominant Epitope of Insulin. Journal of Clinical Investigation. 107(2): 173-180
7. Gottlieb PA and Eisenbarth GS. 2002. Insulin Specific Tolerance in Diabetes. Clinical Immunology, 102 (1): 2-11.
8. Lee PT, Putnam A, Benlagha K, Eisenbarth GS, Gottlieb PA and Bendelac A. 2002.Testing the NKT hypothesis in human IDDM. Journal of Clinical Investigation. 110(6):793-800.
9. Alleva DG, Gaur A, Jin L, Wegmann DR, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA and Conlon PJ. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 51(7):2126-34.
10. Gottlieb PA and Fain PR. 2002. The Genetic Basis of Autoimmune Adrenal Insufficiency. Current Opinion in Endocrinology and Diabetes. 9: 237-243.
11. Garg, SK, Frias, JP, Anil, Sunitha, Gottlieb PA, MacKenzie, T, Jackson, W. 2003. Insulin Lispro Therapy In Pregnancies Complicated By Type 1 Diabetes: Glycemic Control and Maternal and Fetal Outcomes. Endocrine Practice. 9 (3):187-193.
12. Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. 2004. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technology Therapy. 6(1):9-15.
13. Kelemen K, Gottlieb PA, Putnam AL, Davidson HW, Wegmann DR, Hutton JC. 2004. HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2beta) in human prediabetes. Journal of Immunology.15;172(6):3955-62.
14. Vendrame F, Gottlieb PA. 2004. Prediabetes: prediction and prevention trials. Endocrinology and Metabolism Clinics of North America. 33(1):75-92, ix.
15. Gottlieb, PA. 2004. Type 1 diabetes. Endocrinology and Metabolism Clinics of North America.33(1):xiii-xiv.
16. Eisenbarth GS, Gottlieb PA. 2004. Autoimmune polyendocrine syndromes. New England Journal of Medicine. 13;350(20):2068-79.
17. Ott PA, Dittrich MT, Herzog BA, Guerkov R, Gottlieb PA, Putnam AL, Durinovic-Bello I, Boehm BO, Tary-Lehmann M, Lehmann PV. 2004. T cells recognize multiple gad65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading. Journal of Clinical Immunology. 24(4):327-39.
18. Barker JM, Ide A, Hostetler C, Yu L, Miao D, Fain PR, Eisenbarth GS, Gottlieb PA. 2005. Endocrine and Immunogenetic Testing in Individuals with Type 1 Diabetes and 21-Hydroxylase Autoantibodies: Addison's Disease in a High Risk Population. J Clin Endocrinol Metab. 90(1):128-34.
19. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. 2005.CD4+CD25high Regulatory T Cells in Human Autoimmune Diabetes. J. Autoimmunity 24(1):55-62.
20. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG. 2005. Pharmacological Characterization of CXC Chemokine Receptor 3 (CXCR3) Ligands and a Small-Molecule Antagonist. J Pharmacol Exp Ther. 2005 Mar 10; [Epub ahead of print]
21. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenberg E, Nelson JC, Gottlieb PA, Rewers M, Eisenbarth GS. 2005. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 28(4):850-5.
22. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA. 2006. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 63(1):59-69.
23. Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A, Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P and Wiseman A. 2006. Initial results of screening of non – diabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab. May;91(5):1855-61.
24. Liu W, Putnam A, Xu-yu Z, Szot G, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de Groth B, Clayberger C, Ziegler S, and Bluestone JA. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Tregs. J Exp Med. 2006 Jul 10;203(7):1701-11
25. Brusko T, Wasserfall C, McGrail K, Schatz R, Veiner HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M and Atkinson M. 2007. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 56(3):604-12.
C. Research Support
DK60782 DPT-1/TrialNet (Gottlieb ) 09/01/01-06/30/08
NIH/NIDDK
Type 1 Diabetes Prevention Trial
To perform multicenter intervention trials in type 1 diabetes. To determine whether the early intervention use of insulin in non-diabetic relatives of persons with type 1 diabetes can delay their development of type 1 diabetes.
DK60782 Subcontract (Gottlieb) 07/01/2005-06/30/2008
George Washington University/NIH
B-cell ELISpot for the antiCD20 Trial
The T Cell Assay Validation Study is a comparative study between the cytokine ELISpot, Tetramer, Immunoblot, and T Cell Proliferation Assays using fresh blood samples from subjects with recent onset type 1 diabetes mellitus. The primary objective of the study is to assess differences in T cell assays from participants with type 1 diabetes as compared to normal control subjects to asses discriminant validity , and to assess the reproducibility of each assay from repeat collections in the same subject.
R01 DK052068-05A1 (Hutton) 12/1/04-11/30/09
NIH
Cloning of molecular targets of CMI in type 1 diabetes
To determine CD4 and CD8 novel epitopes for T cell responses in Type 1 diabetes using mouse models of disease.
ITN027AI (Phase II) (Herold) 07/1/05-12/31/06
ITN/Immune Tolerance Network
Treatment with hOKT3g1 (Ala-Ala) in T1DM
This study will examine the immunologic effects of humanized FcR non-binding anti-CD3 mAb on immune responses associated with Type 1 diabetes mellitus (T1DM), and develop this therapy to prevent the immune destruction leading to b cell loss.
U19 AI46374 (Holers) 09/28/99-3/31/08
NIH Autoimmunity Core A
Focus on the roles of complement receptors and membrane regulatory proteins in the immune response, with special emphases on B lymphocytes and autoimmune diseases.
Pending
ITN028AI (Gitelman) 07/1/07-9/30/2009
ITN/Immune Tolerance Network
Trial of thymoglobulin for treatment of new onset type 1 diabetes mellitus.
RFA DK06-002 Subcontract (Gottlieb) 09/01/2006-8/31/2008
Brigham and Women’s Hospital/NIH
To examine the costimulatory role of a subset of T cells defines as CD4loCD40+ that are expanded in T1D patients compared to non-autoimmune controls and T2D patients and contains T cell responses to preproinsulin, GAD65 and islets.
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
